It has been reported that multiple insider activity took place at Invacare Corporation (IVC). Senior VP and CFO Leneghan Kathleen P. acquired 6,500 shares for $50,359 in transaction occurred on 2018/11/20. After making this transaction, Senior VP and CFO owns a direct stake of 30 shares, worth $362,080, as per the last closing price. On 2018/11/19 NASTAS CLIFFORD D, Director at IVC, purchased 9,000 shares at an average price of $5.42 per share. The new stake is valued at $282,179.
Chairman, President and CEO, Monaghan Matthew E. had invested in 13,750 shares for $243,897 through a trade on 2018/11/08. Following this activity, the insider holds -1 shares worth $1,753,619 as of recent close.
iShares Core S&P Smallcap ETF revealed as top hedge fund owner in Invacare Corporation (IVC) with a stake of over 1.95M IVC shares as of March 30, with a market value of approx. $16.3M as of today. The second largest holder, American Beacon Small Cap Value Fd, with 1.33M shares which equates to $23.83M worth of the stock. At third is Ivy Small Cap Core Fund, which stood pat with 1.09M shares, a 6.54% position in Invacare Corporation, worth $15.83M. The insider holding in stood at 2.9% while institutions hold 0%.
Invacare Corporation (NYSE:IVC) dropped -7.46% in recent trade and currently has a stock-market value of $241.51M. The shares finished at $7.19, after trading as low as $6.53 earlier in the session. It hit an intraday high Tuesday at $7.71. Trading activity significantly improved as the volume at ready counter increased to 1,375,884 shares versus 503,235 in average daily trading volume over the past 20 days. So far this year, the volume has averaged about 822,152 shares. The stock is now 135.74% above against its bear-market low of $3.05 on December 21, 2018. It has retreated -178.16% since it’s 52-week high of $20 reached in June. Now the market price is down -61.24% on the year and up 67.21% YTD.
IVC stock’s 50 day simple moving average (SMA 50) price is $8.25 and its 200-day simple moving average (SMA 200) price is $9.99. The company’s stock currently has a total float of 33.23M shares. Its weekly volatility is hovering around 7.75% and felt 5.83% volatility in price over a month. On the upside, the share price will test short term resistance at around $7.76. On a downside, the stock is likely to find some support, which begins at $6.58. The failure to get near-term support could push it to $5.96.
It had seen a new analyst call from Needham, which initiated the stock at Buy on January 24. Analysts at KeyBanc Capital Mkts, shed their positive views on August 16 by lowering it fromOverweight to Sector Weight. Analysts at CL King, made their first call about the stock on June 02, recommending it is Accumulate.
Moreover, it trades for 61.98 times the next 12 months of expected earnings. Also, it is trading at rather inexpensive levels at just over 0.66x price/book and 0.25x price/sales. Compared to others, Invacare Corporation is in a different league with regards to profitability, having net margins of -4.5%. To put some perspective around this, the industry’s average net margin is 13.31%. IVC’s ROE is -11.4%, which is also considerably worse than the industry’s ROE of 16.4%. It’s also very liquid in the near term, with a current ratio of 2. The stock has a debt/capital of 0.71.
IVC last reported earnings that exceeded expectations. The company raked in -$0.32 per share, -82.61% change on the same period last year. That was better than consensus for -$0.33. Revenue for the recent quarter stood at $223.42 million, down -6% on last year and below the $229.93 million predicted by analysts. For this quarter, Wall Street analysts forecast revenue in a range of $235.6 million to $251 million, which should be compared with $251 million generated last year. EPS is seen in a range of -$0.33 to -$0.14, against the $0.09 reported a year ago.